logo

SCIENCE CHINA Life Sciences, Volume 62 , Issue 9 : 1253-1256(2019) https://doi.org/10.1007/s11427-019-9597-3

Modification of donor lymphocyte infusion: how to improve the outcome?

More info
  • ReceivedJun 18, 2019
  • AcceptedJul 20, 2019
  • PublishedJul 30, 2019

Abstract

There is no abstract available for this article.


Funded by

grants from the National Key Research and Development Program of China(2017YFA0104500)

National Natural Science Foundation of China(81770189,81621001,81530046)

Collaborative Innovation Center of Hematology China

the Science and Technology Project of Guangdong Province of China(2016B030230003)

and the Project of Health Collaborative Innovation of Guangzhou city(201704020214)


Acknowledgment

This work was partly supported by grants from the National Key Research and Development Program of China (2017YFA0104500) from the Ministry of Science and Technology, National Natural Science Foundation of China (81770189, 81621001, 81530046), Collaborative Innovation Center of Hematology China, the Science and Technology Project of Guangdong Province of China (2016B030230003), and the Project of Health Collaborative Innovation of Guangzhou city (201704020214). We thank the principal investigators and the skilled teams.


Interest statement

The author(s) declare that they have no conflict of interest.


References

[1] Cheng Y., Chen Y., Yan C., Wang Y., Zhao X., Chen Y., Han W., Xu L., Zhang X., Liu K., et al. Donor-derived CD19-targeted T cell infusion eliminates B cell acute lymphoblastic leukemia minimal residual disease with no response to donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Engineering, 2019, 5: 150-155 CrossRef Google Scholar

[2] Ciurea S.O., Schafer J.R., Bassett R., Denman C.J., Cao K., Willis D., Rondon G., Chen J., Soebbing D., Kaur I., et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood, 2017, 130: 1857-1868 CrossRef PubMed Google Scholar

[3] Fu Q., Xu L., Zhang X., Wang Y., Chang Y., Liu K., Huang X.. Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes. Sci China Life Sci, 2018, 61: 569-577 CrossRef PubMed Google Scholar

[4] Goldsmith S.R., Slade M., DiPersio J.F., Westervelt P., Schroeder M.A., Gao F., Romee R.. Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. Bone Marrow Transplant, 2017, 52: 1623-1628 CrossRef PubMed Google Scholar

[5] Huang, X., Guo, N., Ren, H., Zhang, Y., Gao, Z., and Lu, D. (2003). An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chin Med J (Engl) 116, 736–741. Google Scholar

[6] Huang X.J., Liu D.H., Liu K.Y., Xu L.P., Chen H., Han W.. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica, 2007, 92: 414-417 CrossRef PubMed Google Scholar

[7] Kharfan-Dabaja M.A., Labopin M., Polge E., Nishihori T., Bazarbachi A., Finke J., Stadler M., Ehninger G., Lioure B., Schaap N., et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol, 2018, 4: 1245-1253 CrossRef PubMed Google Scholar

[8] Liu Y., Huang X., Fei Q., Xu L., Zhang X., Liu K., Chen Y., Chen H., Wang Y.. Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. Sci China Life Sci, 2019, 62: 691-697 CrossRef PubMed Google Scholar

[9] Qin Y.Z., Wang Y., Xu L.P., Zhang X.H., Chen H., Han W., Chen Y.H., Wang F.R., Wang J.Z., Chen Y., et al. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol, 2017, 10: 44 CrossRef PubMed Google Scholar

[10] Tsirigotis P., Byrne M., Schmid C., Baron F., Ciceri F., Esteve J., Gorin N.C., Giebel S., Mohty M., Savani B.N., et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow TransPlant, 2016, 51: 1431-1438 CrossRef PubMed Google Scholar

[11] Wang Y., Chen H., Chen J., Han M., Hu J.D., Jiong Hu J.D., Huang H., Lai Y., Liu D., Liu Q., et al. The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Lett, 2018, 438: 63-75 CrossRef PubMed Google Scholar

[12] Wang Y., Liu D.H., Fan Z.P., Sun J., Wu X.J., Ma X., Xu L.P., Liu K.Y., Liu Q.F., Wu D.P., et al. Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study. Clin Transplant, 2012a, 26: 635-643 CrossRef PubMed Google Scholar

[13] Wang Y., Liu D.H., Xu L.P., Liu K.Y., Chen H., Zhang X.H., Chen Y.H., Han W., Wang F.R., Wang J.Z., et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant, 2012b, 47: 1099-1104 CrossRef PubMed Google Scholar

[14] Wang Y., Wu D.P., Liu Q.F., Qin Y.Z., Wang J.B., Xu L.P., Liu Y.R., Zhu H.H., Chen J., Dai M., et al. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood, 2014, 124: 1880-1886 CrossRef PubMed Google Scholar

[15] Yan C.H., Liu D.H., Liu K.Y., Xu L.P., Liu Y.R., Chen H., Han W., Wang Y., Qin Y.Z., Huang X.J.. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood, 2012, 119: 3256-3262 CrossRef PubMed Google Scholar

[16] Yan C.H., Liu Q.F., Wu D.P., Zhang X., Xu L.P., Zhang X.H., Wang Y., Huang H., Bai H., Huang F., et al. Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute leukemia. Biol Blood Marrow Transplant, 2017, 23: 1311-1319 CrossRef PubMed Google Scholar

[17] Yan C.H., Wang J.Z., Liu D.H., Xu L.P., Chen H., Liu K.Y., Huang X.J.. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and a. Eur J Haematol, 2013, 7 CrossRef PubMed Google Scholar

[18] Yan C.H., Wang Y., Wang J.Z., Chen Y.H., Chen Y., Wang F.R., Sun Y.Q., Mo X.D., Han W., Chen H., et al. Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. J Hematol Oncol, 2016, 9: 87 CrossRef PubMed Google Scholar

[19] Yu X., Xu L., Chang Y., Huang X., Zhao X.. Rapid reconstitution of NK1 cells after allogeneic transplantation is associated with a reduced incidence of graft-versus-host disease. Sci China Life Sci, 2018, 61: 902-911 CrossRef PubMed Google Scholar

[20] Zhao X.S., Liu Y.R., Zhu H.H., Xu L.P., Liu D.H., Liu K.Y., Huang X.J.. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol, 2012, 91: 183-192 CrossRef PubMed Google Scholar

qqqq

Contact and support